hello world
Provided Content: Content provided by Baystreet. The Globe and Mail was not involved, and material was not reviewed prior to publication.
Stocks in play: MediPharm Labs Corp.
Announced its financial results for the three months ended June 30, 2024. Adjusted EBITDA proved negative $124K in Q2 2024, significantly improved from negative $949K during the three months ended March 31, 2024, and representing 96% growth versus Adjusted EBITDA for the same quarter in 2023. MediPharm Labs Corp. shares T.LABS are trading unchanged at $0.07.
